Information  X 
Enter a valid email address

IQ-AI Limited (IQAI)

  Print      Mail a friend

Friday 27 September, 2019

IQ-AI Limited

FDA Clearance to Market for StoneChecker Software

RNS Number : 9198N
IQ-AI Limited
27 September 2019
 

 

IQ-AI Ltd

("IQ-AI" or the "Company")

 

IQ-AI Announce FDA 'Clearance to Market' For StoneChecker Software

Imaging Biometrics, IQ-AI's Milwaukee based subsidiary, today received notification that the FDA has cleared StoneChecker Software for marketing in the USA.

David Smith, Chief Executive of the operating subsidiaries of IQ-AI stated, "We are delighted that after an exhaustive review of the product, that the FDA has cleared the product for marketing in the USA."

A further announcement will be issued in the next few days, outlining the scale of the market opportunity for the product in the USA and IQ-AI's plans for introduction.

The Directors of the Company accept responsibility for the contents of this announcement.

 

-ENDS-

 

For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

 

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Mark Anwyl

Tel: 020 7220 9797

 

About IQ-AI Ltd 

IQ-AI, Ltd, the parent company of StoneChecker® and Imaging Biometrics®, is focused on advanced and state of the art medical software and services. (IQ-AI.ltd). Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. Please visit www.imagingbiometrics.com for further information.  

 

About Imaging Biometrics™, LLC

Imaging Biometrics, a subsidiary of IQ-AI Limited (LON: IQAI), develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualization software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCCKODBPBKKBCB

a d v e r t i s e m e n t